Reprinted from


**International Non-Proprietary Names for Pharmaceutical Preparations**

In accordance with paragraph 3 of the Procedure for the Selection of Recommended International Non-Proprietary Names for Pharmaceutical Preparations (see Annex 1, page 109), notice is hereby given that the following names are under consideration by the World Health Organization as Proposed International Non-Proprietary Names.

Comments on, or formal objections to, Proposed Names may be forwarded by any person to the Pharmaceutical Section of the World Health Organization within four months from 1 April 1958.

The inclusion of a name in this list does not imply any recommendation for the use of the substance in medicine or pharmacy.

**Proposed International non-proprietary names (Prop. I.N.N.): List 6**

<table>
<thead>
<tr>
<th>Proposed International Non-Proprietary Name (Latin, English)</th>
<th>Chemical Name or Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>aceclofenac</td>
<td>3-(a-(4-nitrophenyl)-β-acetylethyl)-4-hydroxycoumarin</td>
</tr>
<tr>
<td>acetaminophen</td>
<td>2-acetyl-10-(1-trimethylaminopropyl) phenothiazine</td>
</tr>
<tr>
<td>aetersolizidin</td>
<td>2-acetamido-1,3,4-thiadiazole-5-sulfonamide</td>
</tr>
<tr>
<td>acetazolamide</td>
<td>ethylenediamino-(N,N,N,N')-tetra-acetic acid</td>
</tr>
<tr>
<td>acetazolamide</td>
<td>18-oxo-corticoesterone</td>
</tr>
<tr>
<td>aminopyrine</td>
<td>(N,N')-bis-(2-diethylaminoethyl)-oxamide bis-2-chlorobenzyl chloride</td>
</tr>
<tr>
<td>ambroxol</td>
<td>β-diethylaminomethyl-4-amino-2-butoxybenzoate</td>
</tr>
<tr>
<td>ambroxol</td>
<td>2-(di-n-butylamino)-2-(μ-methoxyphenyl)-acetamide</td>
</tr>
<tr>
<td>amoxicillin</td>
<td>1-allyl-3-ethyl-6-amino-2, 4-dioxo-1,2,3,4-tetrahydropyrimidine</td>
</tr>
<tr>
<td>amphotericin</td>
<td>2,5-dimino-4-phenylthiazole</td>
</tr>
</tbody>
</table>

1 Other lists of proposed international non-proprietary names can be found in *Chronicle of the World Health ORG.*, 1953, 7, 297; 1954, 8, 216 and 1955, 11, 28; 1957, 14, 33.
anisometradium
anisometadine
amikanumum
amikanum
azacyclonol
azacyclonol
bemegride
bemegride
benactyzinum
benactyzine
benzomutatum
benzomutate
betazotum
betazote
biotaminervinum
biotaminervine
busulfanum
busulfan
calcii glucopieonas
 calcium glucopieonate
captodiamicum
 captodiame
 carbazochromi salicylas
 carbazochrome salicylate
carbazochromie salicylate
clorambucium
 clorambucil
cloridorminum
 chloridormine
chlorhexidinum
 chlorhexidine
chlorosdamini chloridum
 chlorosdamine chloride
chlorosdamine chloride
chloropracainum
 chloropracaine
chlorotriaminenum
 chlorotrimazine
chloroxylendum
 chloroxylene
 chloroxylene
 cinnofuradionum
 cinnofuradione
cinilini bromidum
 cinilini bromide
corticotrophim-zinci hydroxydum
 corticotrophin-zinc hydroxide
crotantinum
 crotantin
6-amino-1,2,3,4-tetrahydro-3-methyl-1-methylallylpyrimidine-2,4-dione
3-(β-diethylaminomethyl)3-phenylbenzofuran-2-one
ω,ω-diphenyl-α-piperid-4-γ- methanol
4-ethyl-4-methyl-2,6-dioxo-piperidine
2-diethylaminomethylbenzilate
2-(ω-methoxy(oxy)ethylene)oxy)-ethyl p-butilaminobenzoate
3-(β-aminomethyl)-pyrazole
2-diethylaminomethyl α-phenyl-α-piperidinoacaritate
1,4-dimethanesulfonoxbutane
calcium hexahydroxyphostonate
p-butyldithiodiphenylmethyl-2-dimethylaminoethy1 sulfide
adrenochrome monosemicarbazonie sodium salicylate complex
p-ds(2-chloroethyl)-aminophenylbutyric acid
4-[γ-(4-morpholino)propoxy]-3-chlorobiphenyl
1,6-bis-(p-chlorophenyldiguanylo)-hexane
4,5,6,7-tetrachloro-2-(trimethylammonium-ethyl)-N-methyl-isomodoline dichloride
β-diethylaminoethyl 2-chloro-4-aminobenzoate
tri(p-methoxyphenyl)chloroethylene
4-chloro-3,5-dimethylphenol
4-tetrahydro-3(furyl)-1,2-(benzo(c)-cinnolino)-pyrazolidine-3,5-dione
1-methyl-3-benziloyoxyquinolinium bromide
a preparation of purified corticotrophin adsorbed on zinc hydroxide
N-ethyl-N-o-tolyl crotonamide
<table>
<thead>
<tr>
<th>Proposed International Non-Proprietary Name (Latin, English)</th>
<th>Chemical Name or Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>cryofluoraneum</td>
<td>1,2-dichloro-1,2,2-tetrafluoroethane</td>
</tr>
<tr>
<td>cryofluorane</td>
<td></td>
</tr>
<tr>
<td>cyclomethycalamium</td>
<td>3-(2-methylpiperidino)-propyl p-cyclohexyloxybenzoate</td>
</tr>
<tr>
<td>cyclomethycaine</td>
<td></td>
</tr>
<tr>
<td>cycloserine</td>
<td>4-amino-isoxazolidin-3-one</td>
</tr>
<tr>
<td>demecolinum</td>
<td>deacetyl(methylcokhicine)</td>
</tr>
<tr>
<td>demecoline</td>
<td></td>
</tr>
<tr>
<td>deserpidinum</td>
<td>11-desmethoxyreserpine</td>
</tr>
<tr>
<td>derpinidine</td>
<td></td>
</tr>
<tr>
<td>dextromoramide</td>
<td>d-3-methyl-2,2-diphenyl-4-morpholinobutyrylpyrrolidine</td>
</tr>
<tr>
<td>dextromoramide</td>
<td></td>
</tr>
<tr>
<td>dichlorophenum</td>
<td>dl-(5-chloro-2-hydroxyphenyl) methane</td>
</tr>
<tr>
<td>dichlorophen</td>
<td></td>
</tr>
<tr>
<td>dicycloverinium</td>
<td>β-diethylaminoethyl cyclohexyl-cyclo-hexane-carboxylate</td>
</tr>
<tr>
<td>dicycloreverine</td>
<td></td>
</tr>
<tr>
<td>dimethoxacamtum</td>
<td>β-dimethylaminoethoxymethyl phenothiazine-10-carboxylate</td>
</tr>
<tr>
<td>dimethoxacinate</td>
<td></td>
</tr>
<tr>
<td>dioctethidrin</td>
<td>1-(3,4-dihydroxyphenyl)-2-ethylamino-propan-4-ol</td>
</tr>
<tr>
<td>dioctetidrin</td>
<td></td>
</tr>
<tr>
<td>diphenadionum</td>
<td>2-diphenylacetyl-1,3-indandione</td>
</tr>
<tr>
<td>diphenadione</td>
<td></td>
</tr>
<tr>
<td>diphenylpyralinum</td>
<td>N-methylpiperidyl-4-benzhydryl ether</td>
</tr>
<tr>
<td>diphenylpyraline</td>
<td></td>
</tr>
<tr>
<td>dipyrroctethyl</td>
<td>2,3-diacetoxybenzoic acid</td>
</tr>
<tr>
<td>dipyrroctetyl</td>
<td></td>
</tr>
<tr>
<td>dyclominium</td>
<td>p-butoxy-3-piperidinopropiophenone</td>
</tr>
<tr>
<td>dycloning</td>
<td></td>
</tr>
<tr>
<td>ecetbiopati iodidum</td>
<td>α,α-diethyl s-(2-trimethylammonium ethyl) phosphorothiolate iodide</td>
</tr>
<tr>
<td>ecorhanate iodide</td>
<td></td>
</tr>
<tr>
<td>endomycin</td>
<td>an antibiotic substance obtained from cultures of <em>Streptomyces enda</em>, or the same substance produced by any other means</td>
</tr>
<tr>
<td>endomyxin</td>
<td>7-(2-diethylaminoethyl)-theophyllin</td>
</tr>
<tr>
<td>etamiphyllin</td>
<td></td>
</tr>
<tr>
<td>etamiphilin</td>
<td></td>
</tr>
<tr>
<td>ethinamatum</td>
<td>1-ethynylcyclohexyl carbonate</td>
</tr>
<tr>
<td>ethinamate</td>
<td></td>
</tr>
<tr>
<td>ethiochinum</td>
<td>3-ethyl-5-phenylhydantoïn</td>
</tr>
<tr>
<td>ethotoin</td>
<td></td>
</tr>
<tr>
<td>ethylphenacemidum</td>
<td>phénylethylacetyurea</td>
</tr>
<tr>
<td>ethylphenacemide</td>
<td></td>
</tr>
<tr>
<td>ethyrsconum</td>
<td>4,6-dioxo-3-methyl-5,5-dieethyl-1,4,5,6-tetrahydropyridine</td>
</tr>
<tr>
<td>ethypicone</td>
<td></td>
</tr>
<tr>
<td>etoxeridinum</td>
<td>1-[2-(2-hydroxyethoxy)-ethyl]-3-phenylpiperidine-4-carboxylic acid, ethyl ester</td>
</tr>
<tr>
<td>etoxeridine</td>
<td></td>
</tr>
<tr>
<td>florantyrumun</td>
<td>γ-fluoranthren-8-yl-γ-oxobutyric acid</td>
</tr>
<tr>
<td>florantyrene</td>
<td></td>
</tr>
<tr>
<td>Proposed International Non-Proprietary Name (Latin, English)</td>
<td>Chemical Name or Description</td>
</tr>
<tr>
<td>------------------------------------------------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>fludrocortisone acetate</td>
<td>9α-fluoro-17-hydroxy cortisolone 21-acetate</td>
</tr>
<tr>
<td>fludrocortisone acetae</td>
<td>9α-fluoro-11β,17β-dihydroxy-17α-methylandrost-4-ene-3-one</td>
</tr>
<tr>
<td>flutamide</td>
<td>2-formamido-5-nitrothiazole</td>
</tr>
<tr>
<td>formoteronosum</td>
<td>γ-lactone of α-glucosuranaronic acid</td>
</tr>
<tr>
<td>formoteronolactone</td>
<td>3-ethyl-3-phenyl-2,6-dioxo-piperidine</td>
</tr>
<tr>
<td>glutethimide</td>
<td>2-bromo-2-chloro-1,1,1-trifluoroethane</td>
</tr>
<tr>
<td>halothane</td>
<td>bis-1,3-(β-ethylhexyloxy)-5-methyl-5-aminohexahydropyrimidine</td>
</tr>
<tr>
<td>hexetidin</td>
<td>N′-(β-cyclohexyl-β-hydroxy-β-phenylethyl)-N′-dimethylpiperazinium methysulfate</td>
</tr>
<tr>
<td>hexyloxycyanilide</td>
<td>N-pyrrolidylethyl-N-phenylbenzylamine</td>
</tr>
<tr>
<td>histagyluridin</td>
<td>N-methyl-3-aminomethyl-1,2-methylene dioxybenzene</td>
</tr>
<tr>
<td>histagyluridine</td>
<td>17-hydroxycorticosterone 21-diyethylaminocetate hydrochloride</td>
</tr>
<tr>
<td>hydrocortisone hemihydrate</td>
<td>1-(β-Chlorobenzhydryl)-4-[2-(2-hydroxyethoxy)-ethyl] piperazine</td>
</tr>
<tr>
<td>hydrocortisone hydrochloride</td>
<td>a sterile buffered suspension of insulin with zinc chloride and globin</td>
</tr>
<tr>
<td>hydroxyzine</td>
<td>a sterile buffered suspension of insulin with zinc chloride and protamine</td>
</tr>
<tr>
<td>injecto insulin zinc globinatii</td>
<td>2-methylamino-6-methylhept-5-ene</td>
</tr>
<tr>
<td>injecto insulin zinc protaminatii</td>
<td>10-(2-dimethylamino-2-methylpropyl)-1-azaphenothiazine</td>
</tr>
<tr>
<td>慢化硅酸铝酸铝</td>
<td>p-laurylphenyloxyethyl-benzyl-dimethylammonium chloride</td>
</tr>
<tr>
<td>laurotironum</td>
<td>5-formyl-3,5,6,7,8-tetrahydropteroyl-glutamic acid</td>
</tr>
<tr>
<td>lecithin</td>
<td>1-(3-methyl-2,2-diphenyl-4-morpholinobutyryl)pyrrolidine</td>
</tr>
<tr>
<td>levomorphone</td>
<td>1-(4-(4-hydroxy-3-hydroxyoxo)-3,3-diiodophenyl)lactine</td>
</tr>
<tr>
<td>levonamidin</td>
<td>hydroxy aluminium magnesium ammonium acetate</td>
</tr>
<tr>
<td>levonamidin</td>
<td>3-methylaminooxacamphane</td>
</tr>
<tr>
<td>levolithronine</td>
<td>Nα,α-trimethyl-β-phenylethylamine</td>
</tr>
<tr>
<td>magnesium aluminii glycina</td>
<td></td>
</tr>
<tr>
<td>Chemical Name or Description</td>
<td></td>
</tr>
<tr>
<td>-----------------------------</td>
<td></td>
</tr>
<tr>
<td>2-methyl-2-propyl-propane-1,3-diol dicarboxylate</td>
<td></td>
</tr>
<tr>
<td>6-purinethiol</td>
<td></td>
</tr>
<tr>
<td>1,3-dimethyl-3-phenyl-2,5-dioxo-pyrrolidine</td>
<td></td>
</tr>
<tr>
<td>3-(6-methoxy-2-naphthyl)-3-ethyl-2,2-dimethylpropionic acid</td>
<td></td>
</tr>
<tr>
<td>5-methylthiocetyl-5-(2-pentyl)-2-thiobarbituric acid</td>
<td></td>
</tr>
<tr>
<td>hydroxysymethylgranicidin</td>
<td></td>
</tr>
<tr>
<td>2-methoxy-10-(3-dimethylaminopropyl) phenothiazine</td>
<td></td>
</tr>
<tr>
<td>1-p-methoxyphenyl-1-methylamino-propan-1-one</td>
<td></td>
</tr>
<tr>
<td>2-phenyl-α-(2-piperidyl)-methyl acetate</td>
<td></td>
</tr>
<tr>
<td>3,3-diethyl-5-methylpipеридин-2,4-дione</td>
<td></td>
</tr>
<tr>
<td>N-(5-chloro-2-benzimidazolylmethyl)-N-phenyl-Ν,Ν'-dimethyl-ethylene-diamine</td>
<td></td>
</tr>
<tr>
<td>monocetyl ether of hydroquinone</td>
<td></td>
</tr>
<tr>
<td>morpholinomethylnorpathidine</td>
<td></td>
</tr>
<tr>
<td>calcium chelate of the disodium salt of ethylenediamino-Ν,Ν,N',N'-tetra-acetic acid</td>
<td></td>
</tr>
<tr>
<td>di-β-ethylhexyl sodium succinate</td>
<td></td>
</tr>
<tr>
<td>sodium 3,5-dipropionylamino-2,4,6-triodobenzoate</td>
<td></td>
</tr>
<tr>
<td>anionic hexavalent radioactive chromium (⁶⁰Cr) in the form of sodium chromate</td>
<td></td>
</tr>
<tr>
<td>radioactive phosphorus in the form of a mixture of sodium dihydrogen phosphate and disodium hydrogen phosphate</td>
<td></td>
</tr>
<tr>
<td>5-nitro-2-furaldehyde 2-(2-hydroxyethyl) semicarbazone</td>
<td></td>
</tr>
<tr>
<td>2-hydroxyethyltrimethylammonium nitric acid outer perchlorate</td>
<td></td>
</tr>
<tr>
<td>17-α-ethyl-17-hydroxy-19-nor-4-androsten-3-one</td>
<td></td>
</tr>
<tr>
<td>17-α-ethyl-19-nor-4-androsten-17-β-oic-3-one</td>
<td></td>
</tr>
<tr>
<td>an antibiotic substance obtained from cultures of Streptomyces sphalerides, or the same substance produced by any other means</td>
<td></td>
</tr>
</tbody>
</table>
nystatin
nystatin

oleandomycin
oleandomycin

ostreogycin
ostreogycin

oxeladinum
oxeladin

oxycinophen
oxycinophen

pentacyclin chloride
pentacyclin chloride

pentoxevernam
pentoxevernam

petricloral
petricloral

phenacyloclodol
phenacyloclodol

phenamazolin
phenamazolin

phenmetrazin
phenmetrazin

phenbutydidol
phenbutydidol

phenoxybenzamidin
phenoxybenzamidin

phenoxyethylpenicillin
phenoxyethylpenicillin

phensuximidin
phensuximide

phenyltolum
phenyltolone

phenyltoloxamin
phenyltoloxamine

phthaloxybenzimidolum
phthaloxybenzimidole

pimetemidin
pimetemidin

pipenzolat bromidum
pipenzolat bromide

piperazinum calci edetas
piperazine calcium edetate

piperidionum
piperidionate

\textit{Chemical Name or Description}

an antibiotic substance obtained from cultures of \textit{Streptomyces noursei},
or the same substance produced by any other means

an antibiotic substance obtained from cultures of \textit{Streptomyces antibioticus}, or the same substance produced by any other means

an antibiotic substance obtained from cultures of \textit{Streptomyces ostregriseus}, or the same substance produced by any other means

diethylaminoethoxyethyl-s.e-diethyl-phenyl acetate

3-hydroxy-2-phenylquinoline-4-carboxylic acid

\(N'-(5\text{-cyan}-5,5\text{-diphenylpentyl})\text{-}N'\text{-dimethylammoniumethyl}-\text{N-methylmorpohlinium dichloride}\)

2-(2-diethylaminoethoxy)-ethyl 1-phenyl-cyclopentane-1-carboxylate

diethylaminoethoxyethyl-s.e-diethyl-phenyl acetate

\textit{Pentaerythritol chloral}

2-\text{p-chlorophenyl}-3-methylbutane-2,3-diol

2-anilinomethylimidazoline

2-phenyl-3-methyl-morpholine

\((-2,4,6\text{-triiodophenoxy})\text{-}\text{butyric acid}\)

\[N\text{-phenoxyisopropyl-N-benzyl-3-chloroethylamine}\]

an antibiotic in which the benzil group of benzylpenicillin has been replaced by a phenoxyethyl group

1-methyl-3-phenyl-2,5-dioxopyrrolidine

2-ethyl-2-phenyl-thiamorpholine-3,5-dione

2-(\text{o-benzylphenoxy})-ethylidimethylamine

5-phthaloxybenzilamido-2-methyl-1,3,4-thiadiazole

\[N\text{-methyl-N-(3-picolyl)-tropamide}\]

\[N\text{-methyl-N-ethyl-3-piperidinium benzilate bromide}\]

a chelate produced by reacting edetic acid with calcium carbonate and piperazine

\[N\text{-ethylpiperid-3-yl diphenylacetate}\]
pipradrol

polymyxin B

polymyxin B

prednisolone

prednisolone

prednisone

probeneicid

probencid

procloperazine

prochlorperazine

prodeccon bromidum

prodeccon bromidum

promazinum

promazine

promoxolane

propanoic acid

propionamide

propylhexedrinum

propylhexedrine

prothipendylum

prothipendyl

proxymetacaine

proxymetacaine

pyridostigmine

pyridostigmin

pyrvinil chloridum

pyrvinium chloride

racemoradum

racemoramide

rescinnaminum

rescinnamine

spiramycin

spiramycin

streptomodinum

streptomodase

streptokinase

streptokinase

streptomycycin

streptomycycin

suspension insulinum chin zince

insulin zinc suspension
tetrazyzolinum
tetrazyzoline
tetrazyzolium
tetrazyzoline
thenalidinium
thenalidide
thyrotophin
thyrotophin
tolbutamidum
tolbutamide
tolprozinum
tolprozine
tridexethyli iodidum
tridexethyli iodide
trimperidinum
trimperidine
trimetaphan camphorsulfonate
trimetaphan camphorsulfonate
triprolidinum
triprolidine
vancomycinum
vancomycin
verazidum
verazide
zoxazolaminum
zoxazolamine

\(\beta\)-(1,2,3,4-tetrahydroanaphth-1-yl)-2-imidazoline
1-methyl-4-\(N\)-(2-phenyl-anilino)-piperidine
thyrotophin hormone
\(N\)-p-tolysulfonyl-\(N\,\text{-butyl-carbamido}
1-(1,2,3,6-tetrahydropridino)-3-\(N\)-toxyxpropan-2-ol
3-hydroxy-3-phenyl-3-cyclohexyl-propyltrimethylammonium iodide
1,2,5-trimethyl-4-phenyl-4-propionoxypiperidine
\(d\,3,4-(1,3-dibenzyl-2-keto-imidazolidino)-1,2-trimethylene thiophanum
\(d\)-camphorsulfonate
\(trans\)-1-(pyrid-2-yl)-3-pyrrolidino-\(d\,\text{-tolyprop-1-ene}
an antibiotic substance obtained from cultures of Streptomyces orientalis, or the same substance produced by any other means
1-isoscinolino-2-veratrylidene hydrazine
2-amine-5-chlorobenzoxazole

Annex 1

PROCEDURE FOR THE SELECTION OF RECOMMENDED INTERNATIONAL NON-PROPRIETARY NAMES FOR PHARMACEUTICAL PREPARATIONS

The following procedure shall be followed by the World Health Organization in the selection of recommended international non-proprietary names for pharmaceutical preparations, in accordance with the World Health Assembly resolution WHA3.11:

1. Proposals for recommended international non-proprietary names shall be submitted to the World Health Organization on the form provided therefor.

2. Such proposals shall be submitted by the Director-General of the World Health Organization to the members of the Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations designated for this purpose, for consideration in accordance with the "General principles for guidance in devising International Non-proprietary Names", appended to this procedure. The name used by the person discovering or first developing and marketing a pharmaceutical preparation shall be accepted, unless there are compelling reasons to the contrary.

* Text adopted by the Executive Board in resolution EB15.R7 (Off. Rev., 17th Med. Conv., 0, 3)
* See Annex 2, page 111.
3. Subsequent to the examination provided for in article 2, the Director-General of the World Health Organization shall give notice that a proposed international non-proprietary name is being considered:
   A. Such notice shall be given by publication in the Chronicle of the World Health Organization and by letter to Member States and to national pharmacopoeia commissions or other bodies designated by Member States.
   (i) Notice may also be sent to specific persons known to be concerned with a name under consideration,
   B. Such notice shall:
      (i) set forth the name under consideration;
      (ii) identify the person who submitted a proposal for naming the substance, if so requested by such person;
      (iii) identify the substance for which a name is being considered;
      (iv) set forth the time within which comments and objections will be received and the person and place to whom they should be directed;
      (v) state the authority under which the World Health Organization is acting and refer to these rules of procedure.
   C. In forwarding the notice, the Director-General of the World Health Organization shall request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the proposed name during the period it is under consideration by the World Health Organization.

4. Comments on the proposed name may be forwarded by any person to the World Health Organization within four months of the date of publication, under article 3, of the name in the Chronicle of the World Health Organization.

5. A formal objection to a proposed name may be filed by any interested person within four months of the date of publication, under article 3, of the name in the Chronicle of the World Health Organization.
   A. Such objection shall:
      (i) identify the person objecting;
      (ii) state his interest in the name;
      (iii) set forth the reasons for his objection to the name proposed.

6. Where there is a formal objection under article 5, the World Health Organization may either reconsider the proposed name or use its good offices to attempt to obtain withdrawal of the objection. Without prejudice to the consideration by the World Health Organization of a substitute name or names, a name shall not be selected by the World Health Organization as a recommended international non-proprietary name while there exists a formal objection thereto filed under article 5 which has not been withdrawn.

7. Where no objection has been filed under article 5, or all objections previously filed have been withdrawn, the Director-General of the World Health Organization shall give notice in accordance with subsection A of article 3 that the name has been selected by the World Health Organization as a recommended international non-proprietary name.

8. In forwarding a recommended international non-proprietary name to Member States under article 7, the Director-General of the World Health Organization shall:
   A. request that it be recognized as the non-proprietary name for the substance; and
   B. request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the name, including prohibiting registration of the name as a trade-mark or trade-name.
Annex 2

GENERAL PRINCIPLES FOR GUIDANCE IN DEVISING INTERNATIONAL NON-PROPRIETARY NAMES

1. Names should, preferably, be free from any anatomical, physiological, pathological or therapeutic suggestion.

2. An attempt should first be made to form a name by the combination of syllables in such a way as to indicate the significant chemical groupings of the compound and/or its pharmacological classification. Preference should be given to the following syllables:

<table>
<thead>
<tr>
<th>Latin</th>
<th>English</th>
<th>French</th>
</tr>
</thead>
<tbody>
<tr>
<td>inum</td>
<td>ince</td>
<td>ine</td>
</tr>
<tr>
<td>inum</td>
<td>ine</td>
<td>ine</td>
</tr>
<tr>
<td>olum</td>
<td>ol</td>
<td>ol</td>
</tr>
<tr>
<td>alum</td>
<td>al</td>
<td>al</td>
</tr>
<tr>
<td>onum</td>
<td>one</td>
<td>one</td>
</tr>
<tr>
<td>enum</td>
<td>ence</td>
<td>ene</td>
</tr>
<tr>
<td>anum</td>
<td>ane</td>
<td>ane</td>
</tr>
<tr>
<td>caum</td>
<td>caine</td>
<td>caine</td>
</tr>
<tr>
<td>mer</td>
<td>mer</td>
<td>mer</td>
</tr>
<tr>
<td>sulfonum</td>
<td>sulfone</td>
<td>sulfone</td>
</tr>
<tr>
<td>quinum</td>
<td>quine</td>
<td>quine</td>
</tr>
<tr>
<td>crimun</td>
<td>crine</td>
<td>crine</td>
</tr>
<tr>
<td>sulfa</td>
<td>sulfa</td>
<td>sulfa</td>
</tr>
<tr>
<td>diomum</td>
<td>diione</td>
<td>diione</td>
</tr>
<tr>
<td>tolun</td>
<td>toline</td>
<td>toline</td>
</tr>
<tr>
<td>stigminum</td>
<td>stigmine</td>
<td>stigmine</td>
</tr>
</tbody>
</table>

for alkaloids and organic bases
for glycerides and neutral principles
for alcohols and phenols (–OH group)
for aldehydes
for ketones and other substances containing the CO group
for unsaturated hydrocarbons
for saturated hydrocarbons
for local anaesthetics
for mercurial compounds
for sulfone derivatives
for antimalarial substances containing a quinoline group
for antimalarial substances containing an acridine group
for derivatives of sulfanilamide
for anti-epileptics derived from oxazolidinedione
for anti-epileptics derived from hydantoin
for anticholinesterases

3. Names should be distinctive in sound and spelling. They should not be inconveniently long and should not be liable to confusion with names already in use.

4. The addition of a terminal capital letter or number should be avoided as far as possible.

5. Names proposed by the person discovering or first developing and marketing a pharmaceutical preparation, or already officially adopted in any country, or used in the national pharmacopoeias, or in works of reference such as "New and Non-official Remedies", should receive preferential consideration.